Genelux (NASDAQ:GNLX – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Genelux to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, profitability and valuation.
Risk and Volatility
Genelux has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Genelux’s competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Genelux and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
| Genelux Competitors | 9919 | 15313 | 45657 | 1602 | 2.54 |
Genelux presently has a consensus target price of $20.00, suggesting a potential upside of 972.39%. As a group, “Biotechnology” companies have a potential upside of 126.37%. Given Genelux’s stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than its competitors.
Profitability
This table compares Genelux and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -205.85% | -138.79% |
| Genelux Competitors | -12,224.09% | -202.33% | -31.23% |
Insider & Institutional Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Genelux and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Genelux | $10,000.00 | -$32.15 million | -2.17 |
| Genelux Competitors | $740.58 million | $10.45 million | -18.80 |
Genelux’s competitors have higher revenue and earnings than Genelux. Genelux is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Genelux competitors beat Genelux on 7 of the 13 factors compared.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
